CRYOPORT, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
CRYOPORT, INC. (CYRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $3.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-06
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $2.25M, a 5018.18% increase year-over-year.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $947.00K, a 166.01% increase year-over-year.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $528.00K, a 97.20% decline year-over-year.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $3.57M, a 162.26% increase year-over-year.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $4.50M, a 77.79% decline from fiscal 2024.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $20.26M, a 202.93% increase from fiscal 2023.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $6.69M, a 45.99% decline from fiscal 2022.
- CRYOPORT, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $12.38M, a 21.71% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.20M 10-Q · filed 2026-08-06 | $3.73M derived: sum of 3 quarters · filed 2026-08-06 | $7.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $947.00K 10-Q · filed 2026-05-05 | $1.48M derived: sum of 2 quarters · filed 2026-05-05 | $5.05M derived: sum of 3 quarters · filed 2026-05-05 | $5.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.10M derived: sum of 2 quarters · filed 2026-03-05 | $4.14M derived: sum of 3 quarters · filed 2026-08-06 | $4.50M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $3.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.62M derived: sum of 2 quarters · filed 2026-08-06 | $3.97M 10-Q · filed 2025-11-06 | $22.80M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $400.00K 10-Q · filed 2026-08-06 | $19.23M derived: sum of 3 quarters · filed 2026-08-06 | $20.59M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $356.00K 10-Q · filed 2026-05-05 | $19.18M derived: sum of 2 quarters · filed 2026-05-05 | $20.54M derived: sum of 3 quarters · filed 2026-05-05 | |||||
| 2024-12-31 | $18.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $20.19M derived: sum of 2 quarters · filed 2026-03-05 | $20.26M 10-K · filed 2026-03-05 | $20.99M 10-K · filed 2025-03-07 | ||||
| 2024-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.44M 10-Q · filed 2025-11-06 | $1.54M 10-Q · filed 2024-11-07 | |||||
| 2024-06-30 | $76.00K 10-Q · filed 2025-08-12 | $186.00K 10-Q · filed 2024-08-08 | ||||||
| 2023-12-31 | -$2.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $1.09M derived: sum of 2 quarters · filed 2026-03-05 | $2.25M derived: sum of 3 quarters · filed 2026-03-05 | $6.69M 10-K · filed 2026-03-05 | $11.11M 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.14M derived: sum of 2 quarters · filed 2024-11-07 | $9.58M 10-Q · filed 2024-11-07 | $16.88M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.60M 10-Q · filed 2024-08-08 | $12.90M derived: sum of 3 quarters · filed 2025-03-07 | $15.88M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $4.44M 10-Q · filed 2024-05-08 | $11.74M derived: sum of 2 quarters · filed 2025-03-07 | $14.72M derived: sum of 3 quarters · filed 2025-03-07 | $16.05M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $10.28M derived: sum of 2 quarters · filed 2025-03-07 | $11.62M derived: sum of 3 quarters · filed 2025-03-07 | $12.38M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $2.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.32M derived: sum of 2 quarters · filed 2023-11-09 | $5.08M 10-Q · filed 2023-11-09 | $8.45M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.10M 10-Q · filed 2023-08-09 | $5.47M derived: sum of 3 quarters · filed 2024-03-13 | $6.84M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $766.00K 10-Q · filed 2023-05-04 | $4.13M derived: sum of 2 quarters · filed 2024-03-13 | $5.50M derived: sum of 3 quarters · filed 2024-03-13 | $8.16M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $4.74M derived: sum of 2 quarters · filed 2024-03-13 | $7.39M derived: sum of 3 quarters · filed 2024-03-13 | $10.18M 10-K · filed 2024-03-13 | ||||
| 2021-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $4.03M derived: sum of 2 quarters · filed 2022-11-04 | $6.81M 10-Q · filed 2022-11-04 | $6.81K 10-Q · filed 2021-11-04 | $13.23M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.44M 10-Q · filed 2022-08-04 | $5.44K 10-Q · filed 2021-08-06 | $11.86M derived: sum of 3 quarters · filed 2023-02-28 | $14.34M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | $2.78M 10-Q · filed 2022-05-05 | $2.78K 10-Q · filed 2021-05-06 | $9.20M derived: sum of 2 quarters · filed 2023-02-28 | $11.68M derived: sum of 3 quarters · filed 2023-02-28 | $11.68M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $6.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $8.90M derived: sum of 2 quarters · filed 2023-02-28 | $8.90M derived: sum of 3 quarters · filed 2023-02-28 | $10.71M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $2.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $2.48M derived: sum of 2 quarters · filed 2020-11-06 | $4.29M 10-Q · filed 2020-11-06 | $4.83M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.80M 10-Q · filed 2020-08-10 | $2.35M derived: sum of 3 quarters · filed 2022-02-28 | $2.43M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2020-03-31 | $1.80M 10-Q · filed 2020-05-08 | $2.35M derived: sum of 2 quarters · filed 2022-02-28 | $2.43M derived: sum of 3 quarters · filed 2022-02-28 | $4.95M derived: sum of 4 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $541.80K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $621.00K derived: sum of 2 quarters · filed 2022-02-28 | $3.14M derived: sum of 3 quarters · filed 2022-02-28 | $3.17M 10-K · filed 2022-02-28 | $3.16M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $79.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $2.60M derived: sum of 2 quarters · filed 2019-11-12 | $2.62M 10-Q · filed 2019-11-12 | |||||
| 2019-06-30 | $2.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $2.54M 10-Q · filed 2019-08-09 | ||||||
| 2019-03-31 | $21.10K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |